iSpecimen Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.9M | $9.3M | $9.9M | $10.4M | $11.1M |
| Cost of revenue | $1.9M | $5.3M | $4.8M | $4.8M | $5.2M |
| Research and development | — | $1.5M | $1.6M | $1.5M | $879,243 |
| Operating income | -$9.0M | -$12.7M | -$11.2M | -$10.2M | -$5.9M |
| Interest expense | $1,949 | $173,771 | $16,001 | $238,963 | $2.1M |
| Income tax expense | — | — | — | $0 | $0 |
| Net income | -$10.5M | -$12.5M | -$11.1M | -$10.2M | -$9.0M |
| Balance Sheet | |||||
| Cash and equivalents | $6.9M | $1.9M | $2.3M | $15.3M | $27.7M |
| Current assets | $7.0M | $3.6M | $8.2M | $19.7M | $32.9M |
| Total assets | $9.5M | $9.4M | $15.8M | $24.6M | $35.7M |
| Current liabilities | $6.2M | $5.8M | $6.0M | $4.3M | $2.5M |
| Total liabilities | $6.4M | $6.0M | $6.1M | $4.3M | $5.9M |
| Total debt | — | — | — | — | $3.5M |
| Stockholders' equity | $3.1M | $3.3M | $9.7M | $20.3M | $29.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$4.2M | -$8.3M | -$5.8M | -$5.8M | -$10.7M |
| Depreciation and amortization | $68,474 | $65,712 | $117,543 | $22,433 | $45,358 |
| Stock-based compensation | $21,266 | $249,675 | $459,666 | $678,613 | $622,064 |
| Capital expenditure | $454 | $31,546 | $19,478 | $215,504 | $2,550 |
| Free cash flow | -$4.2M | -$8.3M | -$5.8M | -$6.0M | -$10.7M |
| Impairments | — | — | — | — | $0 |
Shares outstanding 1.4M
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.